PredictCan Joins FDA ISTAND Initiative to Advance Liver MPS for Drug Safety
PredictCan Biotechnologies is participating in a 3Rs Collaborative initiative accepted into the FDA ISTAND program, bringing together regulators, technology providers, and industry end-users to evaluate liver microphysiological systems for drug-induced liver injury assessment.